AddedRisk Factors
industrial espionage, interruptions or other system issues, unauthorized access and computer viruses. Such events may be difficult to detect, and once detected, their impact may be difficult to assess and address.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Our inability to timely and responsibly leverage emerging technologies, including generative artificial intelligence, could result in a material adverse effect on our business, and the use of emerging technologies generally could result in regulatory action, legal liability, operational challenges or reputational harm.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Our ability to identify, adopt, and effectively integrate emerging technologies, including generative artificial intelligence (“AI”), into our product development, services, and operations is an important factor in maintaining our competitiveness. If we are unable to timely and responsibly leverage such technologies, our operating results, and growth prospects could be adversely affected. Increased use of AI introduces certain risks, including heightened exposure to cybersecurity threats, data privacy and intellectual property concerns, algorithmic errors or bias leading to flawed outputs or poor decision-making, and increased third-party dependency risks. Additionally, the legal and regulatory landscape governing AI is rapidly evolving in the United States and globally. Changes in, or noncompliance with, applicable laws, regulations, standards, and industry guidance could result in increased compliance costs, operational constraints, liability, or reputational harm. While we have implemented, and expect to continue enhancing, governance, security, and quality control measures related to the use of AI and other emerging technologies, these measures may not be effective in all cases, and we may incur significant costs or face unanticipated consequences as these technologies and their regulatory frameworks continue to develop.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Management transition and our ability to attract and retain key personnel create uncertainties which may negatively impact our business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
•The effects of public health outbreaks, including pandemics and epidemics, and related public and governmental actions could have a material adverse impact on our operations and our business and financial condition in the future.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•The synergies and benefits expected from acquiring HRA Pharma and Gateway may not be realized in the amounts anticipated or at all and integrating HRA Pharma and Gateway's business may be more difficult, time consuming or costly than expected.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Failure to effectively monitor and respond to ESG matters, including our ability to set and meet reasonable goals related to climate change and sustainability efforts, may negatively affect our business and operations.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The effects of public health outbreaks, including pandemics and epidemics, and related public and governmental actions could have a material adverse impact on our operations and our business and financial condition in the future.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Going forward, variants of COVID-19 or other public health incidents, including the actions taken to slow their spread, could have an adverse impact on our financial condition, our supply chains and other operations, our results of operations, consumer demand for our products and our ability to access capital. The magnitude of any such adverse impacts are not determinable, but could be material, depending on: the duration, intensity, and continued spread of the disease; the imposition of business or movement restrictions in various jurisdictions; the ability to develop vaccines and their availability, acceptance and efficacy; the severity and duration of any economic downturn resulting from such pandemic or other public health incidents; the effect of global supply chain and shipping challenges on the Company; the effectiveness of the Company's efforts at mitigation; and other factors, both known and unknown, many of which are likely to be outside our control.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Our ability to manufacture, deliver and sell our products is critical to our success. Damage or disruption to our collective supply or distribution capabilities resulting from pandemics and other health crises, including government
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Management transition creates uncertainties, and any difficulties we experience in managing such transitions may negatively impact our business.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have experienced significant changes to our leadership team over the past several years. Patrick Lockwood-Taylor was appointed President, Chief Executive Officer and Board Member in 2023. In 2024, the Company appointed new leaders of its CSCA and CSCI segments with the appointments of Catherine "Triona" Schmelter as President Consumer Self-Care Americas and Roberto Khoury as President Consumer Self-Care International. We also appointed Charles Atkinson as our new General Counsel and Abbie Lennox as our Chief Science Officer and
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
expanded our Chief Scientific Office, with Allison Ives tasked to head our new Disruptive Growth Team. Additionally, David Ball was appointed as Chief Brand and Digital Officer. Although we believe these leadership transitions are in the best interest of our stakeholders, any change in executive management creates uncertainty. Moreover, changes in our Company as a result of management transition could have a disruptive impact on our ability to implement, or result in changes to, our strategy and could negatively impact our business, financial condition and results of operations.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
Various factors may impact our ability to implement our strategies and realize their anticipated benefits. These factors include circumstances outside of our control such as increased competition, legal developments, government regulation, general economic conditions, increased operating costs or expenses and changes in industry trends or consumer preferences. In addition, implementing these changes will require a significant amount of management time and effort, which may disrupt our business or otherwise divert management’s attention from other aspects of our business, including our other strategic initiatives, possible organic or inorganic growth opportunities, and customer and vendor relationships. Any of the foregoing risks could materially adversely affect our business, results of operations, liquidity, and financial condition.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
The synergies and benefits expected from acquiring HRA Pharma and Gateway may not be realized in the amounts anticipated or at all and integrating HRA Pharma and Gateway's business may be more difficult, time consuming or costly than expected.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedRisk Factors
We may experience challenges integrating the Gateway business and managing our expanded operations, including the acquisition of HRA Pharma. Our ability to realize the benefits expected from the HRA Pharma and Gateway acquisitions will depend, in part, on our ability to successfully integrate the business, control costs and maintain growth. Integrations can be complex and time consuming, and the integration may result in temporarily depressed sales while integration of supply chain and distribution channels take place. Any delays, additional unexpected costs, or other difficulties encountered in the integration process could have a material adverse effect on the Company’s revenues, expenses, operating results and/or financial condition. While the integration of HRA Pharma was completed during 2023, activities related to the integration of Gateway continued into 2024.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedRisk Factors
If we are unable to recognize and adequately respond to such developments, or if our including by adapting existing practices and procedures are not adequate to meet new and changing regulatory requirements, market standards or investor expectations, some of which may be conflicting, we may miss corporate opportunities, become subject to regulatory or market scrutiny, litigation or third-party claims, or incur costs and be exposed to revise operations to meet new or revised standards. legal reputational, operational and financial risks.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Navigating Moreover, stakeholder expectations are not uniform on these matters and continue to diverge across different jurisdictions, and we may be unable to satisfy the varying expectations of all relevant policymakers and other stakeholders has inherent costs, and any actual or perceived failure to successfully navigate such expectations may expose us to negative publicity, shareholder activism, and litigation of or other engagement from stakeholders with opposing views, stakeholders, as well as the potential for civil investigations and enforcement by federal governmental authorities.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
These We have been in the past, are currently, and may be in the future, named in these types of lawsuits lawsuits, which can be costly and divert management attention and other resources away from our business, regardless of their merits, and could result in adverse settlements or judgments. judgments, which could have a material impact on our reputation, business, and results of operation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, after our acquisition of Gateway, Nestlé’s Gateway infant formula plant along with the U.S. and Canadian rights to the GoodStart® infant formula brand and other related formula brands ("Gateway"), in response to the FDA's evolving regulatory expectations on infant formula and observations at our facilities, we have shortened our production campaigns to perform more frequent major cleanings and implemented enhanced product testing and quality procedures, resulting in additional increased production costs and lower reduced production volumes of infant formula than previously anticipated.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We believe these initiatives will reduce operating costs and/or enhance our net sales, operating margins, and earnings; however, certain of these initiatives require substantial costs during implementation, and there can be no assurance any of these initiatives will produce the anticipated benefits. earnings.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If As governments enhance impose new or more stringent regulations on the infant formula industry through actions such as requiring additional testing testing, or compulsory batch-by-batch inspection, or impose additional requirements on revised manufacturing practices, practice standards, our sales and operating margins in this category have been and could in the future be adversely affected as it is costly to comply with such new regulations or requirements, and to develop compliant products and processes for our infant formula products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We believe these initiatives will reduce operating costs and/or enhance our net sales, operating margins, and earnings; however, certain Certain of these initiatives require substantial management time and effort and costs during implementation, and there can be no assurance any of these initiatives will produce the anticipated benefits.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Item 7, 7 Management's Discussion and Analysis of Financial Condition and Results of Operations, in response to the warning letter from the FDA in August 2023 and additional inspection observations at our Wisconsin infant formula facility, we have implemented new protocols and made additional infrastructure investments to address these observations. observations and expect to continue to make such changes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any increase in such costs or delay or failure to achieve the anticipated benefits could have a material adverse effect on materially adversely affect our projected results. business, results of operations, liquidity, and financial condition.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
As a result, we These measures have been experiencing increased costs and lower reduced production volumes volumes, and we expect higher compliance costs moving forward. to continue.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
While all sites have returned to reliable, quality-assured production, we incurred certain extraordinary costs associated with the remediation and enhancement actions and expect higher ongoing operating costs at our infant formula manufacturing sites moving forward.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, an event of default under the Credit Agreement may permit the lenders to refuse to permit additional borrowings under the Revolver (as defined below) or to terminate all commitments to extend further credit under the Revolver. in Item 8.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Perrigo sources some raw materials and finished goods from suppliers in Israel for certain self-care products, including Omeprazole.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
There is potential for some disruption as it relates to in-country logistics, including freight.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Perrigo works to fulfill its vision and purpose as a top-tier consumer self-care company with a focused portfolio based on consumer-led innovation, which meets societal needs for:
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•Access: Perrigo's self-care products and solutions enhance the daily lives of millions of families, empowering them to take control of their health and wellness.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•Value: Perrigo delivers value by helping consumers proactively manage their well-being through affordable and effective self-care solutions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•Reliability: Perrigo ensures the safety and effectiveness of its self-care solutions, best serving its consumers.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
During the first quarter of 2026, we have begun transitioning from a geographic segment reporting structure to a category-based segment view, enabling us to better align our financial disclosures and operational analysis with our product offerings and strategic priorities. The change is being made to stay in alignment with the way our chief operating decision maker intends to make future operating decisions, allocate resources and manage the growth and profitability of the Company. The anticipated change is not expected to have any impact on the Company's historical consolidated financial position, results of operations, or cash flows.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Continuing uncertainties arising from increased tariffs on imported products could have an adverse effect on our Company. In 2025, the U.S. government announced new or additional tariffs on products imported from many countries and individualized "reciprocal" tariffs on countries with which the U.S. has the largest trade deficits. While some tariffs have become effective, others have been temporarily suspended, increased then reduced or permanently repealed. The U.S. government has announced trade agreements with various governments as well as additional tariffs on countries due to geo-political issues. As a result, there continues to be significant volatility and uncertainty regarding the scope, timing, implementation and effective rates of tariffs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Based on current assessments, and excluding any potential impact from future pharmaceutical tariffs that may cover ingredients used in the manufacturing of OTC products, we estimate a gross increase to global cost of goods sold of approximately $30 million to $40 million, on a full-year basis beginning in 2026, updated from the previously estimated range of $50 million to $60 million. We continue to mitigate these impacts through a combination of strategic pricing actions, insourcing to our U.S.-based manufacturing facilities and other supply chain actions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
Operation Stork Speed, a regulatory initiative aimed at strengthening the safety, quality, transparency, and resilience
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
of the U.S. infant formula supply. This initiative intends to review the nutrients used in infant nutrition, expand testing
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
for contaminants, and enhance labelling expectations, and will evaluate potential future regulatory updates. In addition, Operation Stork Speed extends the FDA’s personal importation policy, which allows individuals to import certain infant formula products for personal use, thereby potentially increasing competitive pressures in the U.S. infant formula market. Together, these measures may introduce new compliance and regulatory obligations and may affect competitive dynamics in the U.S. market.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We have been focusing on rebuilding market share, while managing the additional cost and production processes. Although we have gained market share in non-WIC infant formula powder, heightened competition from existing and new entrants, particularly as a result of continued regulatory forbearance allowing imported infant formulas has led to increased supply of infant formula in the United States, and the previously disclosed lost distribution of the Good Start® brand have hindered our efforts to recover our previous market share. On November 5, 2025, we announced a strategic review of our infant formula business focused on a combination of accelerating cash flows and reassessing the previously announced investment in this business, while optimizing portfolio impact and management focus. See Nutrition Network Optimization; Strategic Review below.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In 2025, Perrigo initiated the Nutrition Network Optimization project to optimize our infant formula manufacturing footprint, upgrade packaging capabilities, harmonize quality processes, and enhance our research and development capabilities. On November 5, 2025, we announced a strategic review of our infant formula business. The review will assess a full range of alternatives and is aligned with Perrigo’s ‘Three‑S’ (Stabilize, Streamline, Strengthen) plan and reflects our commitment to disciplined capital allocation and supporting improved return on invested capital and total shareholder return. It will focus on a combination of accelerating cash flows and reassessing the previously announced investment in this business of $240 million, while optimizing portfolio impact and management focus.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
Currently, all our infant formula manufacturing sites are up and running and have returned to reliable, quality-assured production with recent output across our infant formula network near historical levels. Our focus now lies in continuing to rebuild customer service levels and getting these critical products back on the shelves for consumers who need high-quality, affordable infant formula. With production now stabilized, we're driving strategic investments to strengthen the infant formula operations network to ensure the long-term sustainability of a key component of our CSCA business.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
On July 29, 2024, the Antitrust Division of the U.S. Department of Justice advised us that it no longer considers Perrigo a subject or target of the division’s grand jury investigation of antitrust violations in the generic drug industry. That investigation had stemmed from the Company’s Rx Pharmaceuticals business, which was divested in 2021.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
Perrigo has successfully transformed into a pure-play consumer self-care company and is now embarking on the next stage of its self-care journey - evolving to One Perrigo. This evolution will create sustainable, value accretive growth through a business model that better positions the Company to win in self-care.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•$206.1 million decrease, or 4.5%, due primarily to $179.2 million of lower net sales volumes, previously disclosed lost distribution of lower margin products, and a later start to the cough and cold season, primarily impacting the Pain & Sleep Aids, Upper Respiratory Digestive Health, and Oral Care categories compared to the prior year and $108.4 million of lower net sales in U.S. Nutrition category driven by actions to augment and strengthen infant formula network. These factors were partially offset by growth in Women's Health and Skin Care; and
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•$253.0 million decrease, or 8.6%, due primarily to $178.3 million of lower net sales volumes, previously disclosed lost distribution of lower margin products, and a later start to the cough and cold season, primarily impacting the Pain & Sleep Aids, Upper Respiratory Digestive Health, and Oral Care categories compared to the prior year and $108.4 million of lower net sales in U.S. Nutrition category driven by actions to augment and strengthen infant formula network. These factors were partially offset by growth in Women's Health category, primarily driven by new product sales of Opill®; and
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
(1) We updated our global reporting product categories as a result of legacy sales being moved out of Other CSCA and into respective categories. These product categories have been adjusted retroactively to reflect the changes and have no impact on historical financial position, results of operations, or cash flows.
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•Upper Respiratory: Net sales of $500.3 million decreased 10.9% due primarily to 7.3 percentage points reduction from portfolio optimization actions and net lost distribution of lower margin products, in addition to lower consumer demand for cough cold and allergy products. These impacts more than offset strong growth of Nasonex® and Triamcinolone Acetonide in the category;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•Digestive Health: Net sales of $497.4 million decreased 2.0% as higher volumes of antacid and laxative products, including Polyethylene Glycol, were more than offset by 3.4 percentage points reduction from exited product lines and portfolio optimization actions, lost distribution of lower margin products in U.S. Store Brand and lower volume of proton pump inhibitors, including Omeprazole, Esomeprazole and Lansoprazole, despite Perrigo share gains;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•Nutrition: Net sales of $449.5 million decreased 20.2% as increases in net sales of infant formula products as the Company continues to refill store brand and contract customer inventories and regain market share was more than offset by lower shipments to customers in the first half of the year as the Company worked through its infant formula plant remediation plans and a 0.8 percentage points decline from exited product lines in the category;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•Pain and Sleep-Aids: Net sales of $345.5 million decreased 13.0% due primarily to net lost distribution of lower margin products, purposeful SKU prioritization actions and exited product lines, which had an aggregate negative impact of 10.3 percentage points. In addition, inventory reductions by U.S. retail customers resulted in lower net sales of pain and sleep-aid products;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•Women's Health: Net sales of $81.1 million increased 67.0% due primarily to the new product launch of Opill® and higher net sales of feminine hygiene products, partially offset by 3.9 percentage point reduction from exited product lines;
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RemovedMD&A
•$10.0 million decrease from unfavorable foreign currency translation; partially offset by
Read it in 10-K Feb 28, 2025 at sec.govopen_in_new
RewordedMD&A
Future interest Interest rate adjustments of for the 3.150% Senior Notes due 2030 are subject to a 2.0% total cap above the original 3.150% interest rate which would result in an rate, ensuring that the interest rate does not to exceed 5.150% based on certain rating events as specified in the Note’s Supplemental Indenture No. 3, dated as of June 19, 2020, among Perrigo Finance Unlimited Company, Perrigo Company plc and Wells Fargo Bank, National Association, as trustee. 5.150%.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
On November 1, 2024, we completed the The sale of Orion Laboratories Hospital & Specialty Business (the "Hospital & Specialty Business") to General Pharma BidCo Pty Ltd, being an Australian incorporated entity which is ultimately owned by funds managed by Genesis Capital ("Genesis Capital") for total consideration of $13.3 million, which resulted in a pre-tax gain loss of $0.6 $1.6 million, net of professional fees, recorded in Other (income) expense, net on the Consolidated Statements of Operations within our CSCI segment.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In On December 15, 2024, we and the Borrower entered into Amendment No. 2, an Incremental Assumption Agreement 2 to our the Credit Agreement, which established a new tranche of loans under the Term Loan B Facility (the "Term B Loans") and Revolving Credit Agreement that provides for the refinancing which refinanced all of the 2023 Incremental Term B Loans and the 2022 Term B Loans outstanding under the Credit Agreement in the aggregate principal amount of $984.7 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Future interest rate adjustments of the 3.150% Senior Notes due 2030 are subject to a 2.0% total cap above the original 3.150% interest rate which would result in an interest rate not to exceed 5.150% based on This adjustment is contingent upon certain rating events events, as specified outlined in the Note’s Supplemental Indenture No. 3, dated as of June 19, 2020, among Perrigo Finance Unlimited Company, Perrigo Company plc and Wells Fargo Bank, National Association, serving as trustee.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The effective tax rate on the pre-tax loss for the year ended December 31, 2024, increased 2025 decreased when compared to the effective tax rate on the pre-tax loss for the year ended December 31, 2023, 2024, primarily due to the impact of the One Big Beautiful Bill Act ("OBBBA") in 2025 and the net impact of an intercompany intellectual property sale, and sale in 2024, offset by the establishment of a partial full valuation allowance in the United States, offset by States and the impact of audit settlements the goodwill impairment charges in the prior year. 2025.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Perrigo’s unique complementary businesses enables enable each individually to play a specific reinforcing role, where 1) store brands and infant formula generate cash for investments into the Company’s key higher margin, higher growth or ‘High-Grow’ brands, 2) branding and innovation capabilities that deliver both brand and store brand demand generation leading designed to lead to stronger customer partnerships, 3) consumer-led innovation that is scaled across brands, store brands and geographies, and 4) the Company’s leveraging global supply chain scale and reach with 100-plus molecules, of more molecules at 100% consumer more price point coverage, serves the most consumers. points to more consumers driving household penetration.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net sales of $282.1 $288.2 million decreased 5.7%, increased 2.1%, inclusive of a 1.1% 4.0% favorable effect of currency translation, due primarily to lower net sales of cough cold products stemming from lower incidence of cough cold throughout the E.U. compared to the prior year, partially offset by higher net sales as well as an unfavorable impact of Bronchenolo®, Bronchostop® 1.5% from divested businesses and Coldrex® which benefited from category growth and market share gains; exited product lines.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The $156.3 $154.2 million increase decrease in cash from investing cash flow was due primarily to the absence of the proceeds from the sale of the Rare Diseases and Hospital & Specialty Businesses, proceeds from Businesses and the sale of six branded products in the current year, partially offset by the settlement of foreign currency derivatives and purchase of an intangible asset in the current year. prior year period.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The $42.6 $124.4 million decrease in operating cash inflow was primarily driven by a decrease in cash flow from the change in net earnings after adjustments for items including deferred income taxes, restructuring charges, settlement of interest rate derivatives, the gain on sale of branded products in addition to higher working capital, primarily related to restructuring costs. impairment, depreciation and amortization, and restructuring.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
All planned large-scale manufacturing plant improvements were completed in 2024, but the Company continues to implement the next phase of our resets have been completed, we have implemented quality enhancements, including further protocol, process and procedural improvements at the site level, and make additional investments to upgrade infrastructure. all sites are producing reliable, quality-assured product.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended (in millions) December 31, 2024 2025 December 31, 2023 2024 $ Change Net cash from operating activities $ 238.5 $ 362.9 $ 405.5 $ (42.6) (124.4) Net cash (for) from (for) investing activities (75.4) 78.8 (77.5) 156.3 (154.2) Net cash from (for) for financing activities (220.5) (611.0) (187.2) (423.8) 390.5 Effect of exchange rate changes on cash and cash equivalents 32.5 (23.2) 9.8 (33.0) 55.7 Net increase (decrease) decrease in cash and cash equivalents $ (24.9) $ (192.5) $ 150.6 $ (343.1) 167.6
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Project Energize was initiated in the first quarter delivered approximately $167 million of 2024, subject to local law and consultation requirements, and is expected to deliver annualized pre-tax savings in as of the end of fiscal year 2025, within the estimated range of $140 million to $170 million expected by the end of 2026.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new